Topotecan hydrochloride hydrate
SIGMA/T2705 - ≥98% (HPLC and enzymatic)
Synonym: 9-
CAS Number: 123948-87-8 (free base)
Empirical Formula (Hill Notation): C23H23N3O5 · xHCl · yH2O
Molecular Weight: 421.45 (anhydrous free base basis)
MDL Number: MFCD00870670
Linear Formula: C23H23N3O5 · xHCl · yH2O
Product Type: Chemical
assay | ≥98% (HPLC and enzymatic) |
color | yellow |
form | powder |
InChI | 1S/C23H23N3O5/c1-4-23(30) |
InChI key | UCFGDBYHRUNTLO-QHCPKHFHSA |
originator | GlaxoSmithKline |
Quality Level | 100 |
solubility | DMSO: ≥20 mg/mL |
storage condition | desiccated |
protect from light | |
storage temp. | −20°C |
Application: | Topotecan has been used as a positive control for the identification and analysis of HIF-1α and VEGF inhibitors in human glioma cells under hypoxic conditions1. It has also been used for in vitro apoptosis assays in PA317 cells2. |
Biochem/physiol Actions: | Topotecan is a topoisomerase I inhibitor and an apoptosis inducer. It is a potent antineoplastic agent. |
Features and Benefits: | This compound is a featured product for ADME Tox and Apoptosis research. Discover more featured ADME Tox and Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm . |
Features and Benefits: | This compound was developed by GlaxoSmithKline . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
Packaging: | 10, 50 mg in glass bottle |
Preparation Note: | Topotecan hydrochloride hydrate is soluble in DMSO at a concentration that is greater than or equal to 20 mg/ml. |
Symbol | GHS08 |
Signal word | Warning |
Hazard statements | H341 |
Precautionary statements | P201 - P308 + P313 |
Risk Statements | 46-48 |
Safety Statements | 22-36 |
RIDADR | NONH for all modes of transport |
WGK Germany | WGK 3 |
Flash Point(F) | Not applicable |
Flash Point(C) | Not applicable |
Purity | ≥98% (HPLC and enzymatic) |
Storage Temp. | −20°C |
UNSPSC | 12352200 |